Multi-scale Computational Models of Pro-angiogenic Treatments in Peripheral Arterial Disease

The induction of angiogenesis is a promising therapeutic strategy for the amelioration of peripheral arterial disease (PAD). This occlusive disease results in muscle ischemia, and neovascularization is a route to increasing the perfusion in the tissue. The vascular endothelial growth factor (VEGF) family of potent pro-angiogenic cytokines is a potential therapeutic agent, increasing VEGF-receptor signaling on tissue vasculature. To investigate the effects of possible therapies on the VEGF concentrations and gradients within the tissue, we consider three such strategies: VEGF gene therapy (e.g. by adeno-associated virus); VEGF cell-based therapy (injected myoblasts that overexpress VEGF); and chronic exercise (which upregulates VEGF receptor expression). The multi-scale computational model used to investigate these strategies is an integration of several components: an anatomical description of the muscle geometry and cell types; microvascular blood flow; tissue oxygen distribution; VEGF secretion from muscle fibers; VEGF transport through interstitial space; and VEGF-receptor binding on microvascular endothelial cells. Exercise training, which results in increased VEGF secretion in hypoxic tissue and increased VEGF receptor expression, exhibits increases in both VEGF concentration and VEGF gradients, and is predicted to be more effective than the other, VEGF-only treatments.

[1]  N. Banchero,et al.  The distribution of diffusion distances in the gastrocnemius muscle of various mammals during maturation , 1982, Pflügers Archiv.

[2]  Y. Kan,et al.  Adeno-associated viral vector-mediated gene transfer of VEGF normalizes skeletal muscle oxygen tension and induces arteriogenesis in ischemic rat hindlimb. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  Aleksander S Popel,et al.  A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1α , 2006, Journal of Cell Science.

[4]  T. Skalak,et al.  The FASEB Journal express article 10.1096/fj.03-0933fje. Published online February 6, 2004. Multicellular simulation predicts microvascular patterning and in silico tissue assembly , 2022 .

[5]  Henning Langberg,et al.  Exercise but not Prostanoids Enhance Levels of Vascular Endothelial Growth Factor and other Proliferative Agents in Human Skeletal Muscle Interstitium , 2003, The Journal of physiology.

[6]  P. Lloyd,et al.  Angiogenic growth factor expression in rat skeletal muscle in response to exercise training. , 2003, American journal of physiology. Heart and circulatory physiology.

[7]  S. Rajagopalan,et al.  Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial. , 2003, American heart journal.

[8]  O. Hudlická,et al.  Hypoxia and Expression of Vegf‐A Protein in Relation to Capillary Growth in Electrically Stimulated Rat and Rabbit Skeletal Muscles , 2002, Experimental physiology.

[9]  M. Flessner,et al.  In vivo diffusion of immunoglobulin G in muscle: effects of binding, solute exclusion, and lymphatic removal. , 1997, American journal of physiology. Heart and circulatory physiology.

[10]  V. Cristini,et al.  Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-element/level-set method , 2005, Bulletin of mathematical biology.

[11]  J. Regensteiner,et al.  Current medical therapies for patients with peripheral arterial disease: a critical review. , 2002, The American journal of medicine.

[12]  Seng H. Cheng,et al.  Expression of constitutively stable hybrid hypoxia-inducible factor-1alpha protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury. , 2005, American journal of physiology. Cell physiology.

[13]  W. Schaper,et al.  Collateral Artery Growth (Arteriogenesis) After Experimental Arterial Occlusion Is Impaired in Mice Lacking CC-Chemokine Receptor-2 , 2004, Circulation research.

[14]  E. Rebar,et al.  Engineered Zinc Finger–Activating Vascular Endothelial Growth Factor Transcription Factor Plasmid DNA Induces Therapeutic Angiogenesis in Rabbits With Hindlimb Ischemia , 2004, Circulation.

[15]  P. Quax,et al.  Vascular Endothelial Growth Factor Overexpression in Ischemic Skeletal Muscle Enhances Myoglobin Expression In Vivo , 2004 .

[16]  E. Weibel,et al.  Capillary tortuosity in skeletal muscles of mammals depends on muscle contraction. , 1989, Journal of applied physiology.

[17]  T. Osawa,et al.  Comparison of the thickness of basement membranes in various tissues of the rat. , 2003, Journal of Electron Microscopy.

[18]  B. J. Limberg,et al.  Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). , 2001, The Journal of biological chemistry.

[19]  Benjamin J. Kraus,et al.  Impaired Revascularization in a Mouse Model of Type 2 Diabetes Is Associated With Dysregulation of a Complex Angiogenic-Regulatory Network , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[20]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[21]  D. Desplanches,et al.  Effect of spontaneous recovery or retraining after hindlimb suspension on aerobic capacity. , 1987, Journal of applied physiology.

[22]  J. Isner,et al.  Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. , 1999, The American journal of pathology.

[23]  K. Ward,et al.  Resonance Raman spectroscopy: A new technology for tissue oxygenation monitoring* , 2006, Critical care medicine.

[24]  E. Crivellato,et al.  Angiogenesis in rheumatoid arthritis. , 2006, Histology and histopathology.

[25]  S. Egginton,et al.  Association between Shear Stress, Angiogenesis, and VEGF in Skeletal Muscles In Vivo , 2001, Microcirculation.

[26]  Jeffrey A Hubbell,et al.  Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1alpha variant for local induction of angiogenesis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Shay Soker,et al.  VEGF165 mediates formation of complexes containing VEGFR‐2 and neuropilin‐1 that enhance VEGF165‐receptor binding , 2002, Journal of cellular biochemistry.

[28]  Aleksander S Popel,et al.  Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model. , 2005, American journal of physiology. Heart and circulatory physiology.

[29]  K. Alitalo,et al.  VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia , 2003, The Journal of cell biology.

[30]  S. Harper,et al.  VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. , 2006, Molecular vision.

[31]  A. Popel,et al.  Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. , 2007, American journal of physiology. Heart and circulatory physiology.

[32]  T. K. Hunt,et al.  Correlation of a simple direct measurement of muscle pO(2) to a clinical ischemia index and histology in a rat model of chronic severe hindlimb ischemia. , 2002, Journal of vascular surgery.

[33]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[34]  G. Hughes,et al.  Angiogenic therapy for coronary artery and peripheral arterial disease , 2005, Expert review of cardiovascular therapy.

[35]  H. Haider,et al.  Therapeutic Angiogenesis for Treatment of Peripheral Vascular Disease , 2004, Growth factors.

[36]  H. Blau,et al.  Critical role of microenvironmental factors in angiogenesis , 2005, Current atherosclerosis reports.

[37]  J. Ferziger Numerical methods for engineering application , 1981 .

[38]  J. Huh,et al.  Efficient expression of the vascular endothelial growth factor gene in vitro and in vivo, using an adeno-associated virus vector. , 2001, Journal of molecular and cellular cardiology.

[39]  J. Pearlman,et al.  Impact of Mouse Strain Differences in Innate Hindlimb Collateral Vasculature , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[40]  A. Whittemore Presidential address: a team for the 21st century: the vascular center. , 2000, Journal of vascular surgery.

[41]  A. Fuglevand,et al.  Oxygen delivery to skeletal muscle fibers: effects of microvascular unit structure and control mechanisms. , 2003, American journal of physiology. Heart and circulatory physiology.

[42]  Hendrik B. Sager,et al.  Collateral arteries grow from preexisting anastomoses in the rat hindlimb. , 2002, American journal of physiology. Heart and circulatory physiology.

[43]  S. Egginton,et al.  Differential expression of Flk-1 and Flt-1 in rat skeletal muscle in response to chronic ischaemia: favourable effect of muscle activity. , 2003, Clinical science.

[44]  Aleksander S Popel,et al.  A computational model of oxygen transport in skeletal muscle for sprouting and splitting modes of angiogenesis. , 2006, Journal of theoretical biology.

[45]  Imo E. Hoefer,et al.  Role of Ischemia and of Hypoxia-Inducible Genes in Arteriogenesis After Femoral Artery Occlusion in the Rabbit , 2001, Circulation research.

[46]  A. Popel,et al.  Dimerization of VEGF receptors and implications for signal transduction: a computational study. , 2007, Biophysical chemistry.

[47]  Shuyu Sun,et al.  A deterministic model of growth factor-induced angiogenesis , 2005, Bulletin of mathematical biology.

[48]  B. J. Limberg,et al.  Vascular Endothelial Growth Factor Receptor-2 and Neuropilin-1 Form a Receptor Complex That Is Responsible for the Differential Signaling Potency of VEGF165 and VEGF121 * , 2001, The Journal of Biological Chemistry.

[49]  M. Gassmann,et al.  HIF and VEGF relationships in response to hypoxia and sciatic nerve stimulation in rat gastrocnemius , 2004, Respiratory Physiology & Neurobiology.

[50]  Aleksander S Popel,et al.  Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise. , 2007, American journal of physiology. Heart and circulatory physiology.

[51]  E. Paleolog Angiogenesis in rheumatoid arthritis , 2002, Arthritis research.

[52]  G. Semenza,et al.  Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O 2 tension , 2002 .

[53]  O. Hudlická,et al.  A New Model of Peripheral Arterial Disease: Sustained Impairment of Nutritive Microcirculation and Its Recovery by Chronic Electrical Stimulation , 2005, Microcirculation.

[54]  A. Pries,et al.  Microvascular blood viscosity in vivo and the endothelial surface layer. , 2005, American journal of physiology. Heart and circulatory physiology.

[55]  A. Popel,et al.  Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. , 2004, American journal of physiology. Heart and circulatory physiology.

[56]  M. Simons,et al.  Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. , 2005, Cardiovascular research.

[57]  S. Ylä-Herttuala,et al.  HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. , 2004, Atherosclerosis.

[58]  Jennifer L. Doyle,et al.  Regulators of angiogenesis and strategies for their therapeutic manipulation. , 2006, The international journal of biochemistry & cell biology.

[59]  O. Mathieu-Costello,et al.  Differential microvascular response to disuse in rat hindlimb skeletal muscles. , 1999, Journal of applied physiology.

[60]  K. Peters,et al.  Preclinical models of human peripheral arterial occlusive disease: implications for investigation of therapeutic agents. , 2004, Journal of applied physiology.

[61]  Lena Claesson-Welsh,et al.  Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. , 2006, Experimental cell research.

[62]  Holger Gerhardt,et al.  Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. , 2002, Genes & development.

[63]  P. Campochiaro,et al.  Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1 , 2006, Gene Therapy.

[64]  Brian H Annex,et al.  Plasticity of myocytes and capillaries: a possible coordinating role for VEGF. , 2004, Circulation research.

[65]  Napoleone Ferrara,et al.  VEGF as a Therapeutic Target in Cancer , 2005, Oncology.

[66]  R. Rutherford,et al.  Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). , 2000, Journal of vascular surgery.

[67]  G. Semenza,et al.  Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. , 1996, The American journal of physiology.

[68]  H. T. Yang,et al.  What makes vessels grow with exercise training? , 2004, Journal of applied physiology.

[69]  H. Blau,et al.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. , 2004, The Journal of clinical investigation.

[70]  Christopher G Ellis,et al.  Automated Method for Tracking Individual Red Blood Cells Within Capillaries to Compute Velocity and Oxygen Saturation , 2005, Microcirculation.

[71]  P. Quax,et al.  Vascular endothelial growth factor overexpression in ischemic skeletal muscle enhances myoglobin expression in vivo. , 2004, Circulation research.

[72]  Aleksander S Popel,et al.  VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. , 2007, Journal of applied physiology.